S100A9 and early-onset autosomal dominant Alzheimer disease: YKL-40 effects are further complicated by the YKL-40 inhibition of Receptor for advanced glycation end products (RAGE) activation by S100A9 [200], which may be more relevant in Alzheimer’s disease than ALS [201].